Default company panoramic image

Arecor Ltd

Arecor provides competitive advantage for major pharma companies by developing and licensing stable liquid formulations of protein drugs

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location United Kingdom
  • Currency GBP
  • Founded May 2007
  • Employees 17
  • Website

Company Summary

Arecor earns revenue undertaking feasibility studies for major pharmaceutical and vaccine companies leading to licenses to Arecor's proprietary technology which provides stable liquid forms of proteins, peptides and vaccines. Many proteins are unstable in liquid form which limits development or more convenient delivery. Arecor is working with 10 of the top 20 pharmaceutical companies and has licenses with Genzyme, GSK Bio and Lilly.


  • Default avatar
    Tom Saylor

    An experienced CEO with a background building entrepreneurial organizations including fundraising, strategy development, licensing, and M&A in Asia, Europe and the United States. Previously, he was CEO of Sirus Limited, a drug targeting and delivery company and Lotus Healthcare Corporation, a fully integrated pharma company in Asia. He has an MBA from Harvard and doctoral studies at Max Planck Institute. Tom is a board member of EuropaBio.

  • Default avatar
    Dr. Sarah Howell

    Sarah has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She was VP for CMC (Chemistry, Manufacturing and Controls) of BTG plc. and Director of Outsourced Manufacturing at UCB. She started her career in API process development at Glaxo Smith Kline. She holds a PhD in Physical Organic Chemistry from St Andrews.

  • Default avatar
    Dr. Jan Jezek

    Jan, the principal inventor of the core protein stabilisation technologies, is a biochemist with a strong background in physical chemistry. Previously he was a Principal Scientist at Insense Limited. Holds a joint Doctorate from the Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester).

  • Default avatar
    Dr. Stephen Dowd
    Business Development

    Stephen had 10 years experience in scientific roles with GSK prior to undertaking an MBA at the University of Cambridge. He brings a solid understanding of the science and needs of major pharmaceutical companies to building the commercial relationships for Arecor. In addition to his MBA Stephen holds a PhD in Molecular Cell Biology from the University of Dundee.


  • Default avatar
    Fiona Crawley, Bryan Cave LLP
    Default avatar
    Lakin Rose Limited

Previous Investors

  • Default avatar
    Unilever Ventures
    Default avatar
    Oxford Technology VCT
    Default avatar
    Hygea VCT